Home > Quotes > DCPH

Deciphera Pharmaceuticals, Inc. Common Stock Quote & Summary Data

Get DCPH Alerts
*Delayed - data as of Dec. 11, 2017 10:51 ET  -  Find a broker to begin trading DCPH now
Industry: Health Care
Community Rating:
View:    DCPH Real Time
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
Basic Chart Interactive Chart
Company Headlines Press Releases Market Stream
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Intraday Chart

Shares Traded

Trading Range

The current last sale of $18.3803 is 14.09% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 19.36 $ 24.50
 Low: $ 17.655 $ 16.11

Company Description (as filed with the SEC)

We are a clinical-stage biopharmaceutical company developing new drugs to improve the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response of many cancer therapies. Our targeted, small molecule drug candidates, designed using our proprietary kinase switch control inhibitor platform, inhibit the activation of kinases, an important family of enzymes, that when mutated or over expressed, are known to be directly involved in the growth and spread of many cancers. We have built a diverse pipeline of wholly owned, orally administered drug candidates that includes three clinical-stage and two research-stage programs. We have designed our lead drug candidate DCC-2618 to inhibit the full spectrum of mutant or amplified KIT and PDGFR? kinases that drive cancers such as gastrointestinal stromal tumors, or GIST. We are studying DCC-2618 in an ongoing Phase 1 trial in patients with advanced malignancies.  ... More ...  

Risk Grade

Where does DCPH fit in the risk graph?

Risk Grade Scale

Nasdaq Official Price

Consensus Recommendation

Analyst Info